Pharmanutra

Regulatory Filings • Jun 13, 2024

Informazione Regolamentata n. 20106-23-2024	Data/Ora Inizio Diffusione 13 Giugno 2024 14:50:33		Euronext Star Milan
Societa'	:	PHARMANUTRA
Identificativo Informazione Regolamentata	:	192181
Utenza - Referente	:	PHARMANUTRAN04 - Roberto Lacorte
Tipologia	:	REGEM
Data/Ora Ricezione	:	13 Giugno 2024 14:50:33
Data/Ora Inizio Diffusione	:	13 Giugno 2024 14:50:33
Oggetto	:	Pharmanutra_Clinical study on SiderAL
Testo del comunicato

Vedi allegato

PHARMANUTRA S.P.A.: A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS

Pisa, 13 June 2024 - PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialising in the field of iron-based nutritional supplements and medical devices for muscles and joints, announces the publication of an important new scientific study on SiderAL®'s direct comparison with other competing oral ironbased products.

This is a spontaneous retrospective observational clinical study conducted by Dr. Manoj A. Suva of the Pharmacology Unit of the University of Rajkot (India) involving 260 patients who had mild to moderate iron deficiency anaemia (haemoglobin values between 7 and 10 g/dL) and randomised into 4 different treatment groups.

The first group was treated with ascorbate iron (equal to 100 mg of elemental iron), the second with fumarate iron (equal to 50 mg of elemental iron), the third group with bisglycinate iron (30 mg of elemental iron) and the last with Sucrosomial® iron (30 mg of elemental iron). The study was aimed at assessing the efficacy and tolerability of the iron supplement treatments examined by analysing the haematochemical parameters at baseline (T0) and after 3 months of treatment (T1).

The results showed that haemoglobin values after 3 months of supplementation improved significantly in the group treated with SiderAL® compared to the other conventional iron salts.

Moreover, these important results about SiderAL's superiority over the other products in the study were obtained by using a lower dosage of Sucrosomial® iron (30 mg) than ascorbate iron and fumarate iron (100 mg and 50 mg, respectively), thus proving to be more effective even at low doses.

Overall gastrointestinal adverse effects were reported by 52 subjects in the study, but only 6 of these related to Sucrosomial® iron, thus leading to SiderAL® having the lowest percentage of gastrointestinal adverse effects compared to the other oral iron supplements.

The authors concluded that SiderAL® proved to be effective, superior and with improved tolerability than conventional iron supplement treatments in improving haematological parameters in subjects with iron deficiency anaemia.

The study is published in an international peer-reviewed journal and can be downloaded at https://link.springer.com/article/10.1007/s40199-024-00517-y.

"This important independent study conducted by Dr. Manoj A. Suva is a source of great satisfaction for the entire company and is yet another, but no less important, confirmation of the extraordinary efficacy of our oral iron", states Andrea Lacorte, Chairman of Pharmanutra S.p.A. "There are now several studies involving our Sucrosomial Technology, a key asset for PharmaNutra, and they all have the same, outstanding results, which is the actual basis for the success of our SiderAL-branded products. By the way, such a technology has a potential that is still partly to be explored, with various applications. This makes us look to the future of our company with increasing confidence".

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomial® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The effectiveness of the products is demonstrated by a number of scientific evidences, including more than 120 publications. In Italy, the sales activity is carried out through a network of over 160 Pharmaceutical Sales Representatives serving the medical class and dedicated to the exclusive marketing of products to pharmacies and parapharmacies throughout the national territory. Sales abroad are guaranteed in over 71 countries through 45 partners selected among the leading pharmaceutical companies. Over the years, the Group has developed a precise strategy in the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence. PharmaNutra.it

For further information:

Via Campodavela, 1 - 56122 Pisa, Italy Tel. +39 050 7846500 investorrelation@pharmanutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com

PharmaNutra S.p.A. Registered office Via Campodavela, 1 - 56122 Pisa, Italy | +39 050 7846500 pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it Tax ID no. / VAT no. / Trade Reg. no. 01679440501 - SDI Code SUBM70N Sh. Cap. 1,123,097.70 € fully paid in | REA Economic and Administrative Index 146259

	Fine Comunicato n.20106-23-2024	Numero di Pagine: 4
--	---------------------------------	---------------------